Vineti, Cryoport partner to extend end-to-end cell therapy logistics offering

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Vineti, Cryoport, Logistics, Supply chain

A collaboration between Vineti and Cryoport aims to extend supply chain services as the cell and gene therapies space continues to scale.

Cold-chain logistics provider Cryoport announced a partnership with Vineti, a software developer with a cloud-based platform enabling the integration of logistics, manufacturing, and clinical data for cell and gene therapies.

The partnership is expected to pair Vineti’s supply chain orchestration (SCO) platform with Cryoport’s temperature-controlled logistics, with the aim to support the assurance of quality and safety of their clients’ drug products.

“We intend to provide a range of different options for how data is accessed between each platform, with biopharmaceutical clients able to select the types of data displays that reflect their specific needs,”​ Amy DuRoss, CEO and co-founder of Vineti, told us.

The partnership looks to meet demands of cell and gene therapy developers, which are becoming ‘increasingly complex’ as the regenerative medicine market matures, according to Jerrell Shelton, CEO of Cryoport.

In order to ensure chain of identity and chain of custody, “patient-centric supply chain must be maintained, traced, and documented,”​ Mark Sawicki, Cryoport’s CCO told us.

According to Sawicki, ”This partnership will give biopharmaceutical teams an end-to-end view, and allow visibility from key points in the therapeutic product process.”

“[The partnership] will also provide the teams with the ability to sync and seamlessly transfer data between two systems without human error, with the ultimate goal of consolidating data streams,” ​Sawicki added.

Vineti’s platform will be accessible to customers operating in both clinical and commercial stage, due to Cryoport supporting an estimated 400 clinical trials as well as three commercialized products, including Novartis’ Kymriah and Kite’s Yescarta, the first two cell therapies available​ on the market.

Building on a partners network

Vineti was established by GE Ventures and the Mayo Clinic in 2017, and earlier this year​ was selected by the World Economic Forum as a global technology pioneer.

This year also saw Vineti partner​ with contract development and manufacturing organisation (CDMO) Lonza, in order for the latter to further boost its services offered to clients developing cell and gene therapies.

DuRoss told us then​ that the industry needs to focus on incorporating industrialized supply chain capabilities, concurrently with adopting standardized systems to manage all of the products moving along the supply chain.

According to Vineti, its platform is expected to be in use by more than 300 clinical centers worldwide within the next year.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars